Dysfunctional uterine bleeding secondary prevention

Jump to navigation Jump to search

Dysfunctional uterine bleeding Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Dysfunctional uterine bleeding from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Dysfunctional uterine bleeding secondary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Dysfunctional uterine bleeding secondary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Dysfunctional uterine bleeding secondary prevention

CDC on Dysfunctional uterine bleeding secondary prevention

Dysfunctional uterine bleeding secondary prevention in the news

Blogs on Dysfunctional uterine bleeding secondary prevention

Directions to Hospitals Treating Dysfunctional uterine bleeding

Risk calculators and risk factors for Dysfunctional uterine bleeding secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Arooj Naz, M.B.B.S

Overview

Secondary prevention occurs once the disease has developed and aims to prevent progression and development of further complications. Complications due to abnormal uterine bleeding include infertility, anemia, and malignancy.

Secondary prevention

DUB-based complications can be treated by:

References

  1. Albers JR, Hull SK, Wesley RM (2004). "Abnormal uterine bleeding". Am Fam Physician. 69 (8): 1915–26. PMID 15117012.
  2. "StatPearls". 2022. PMID 28846348.
  3. Sjögren LL, Mørch LS, Løkkegaard E (2016). "Hormone replacement therapy and the risk of endometrial cancer: A systematic review". Maturitas. 91: 25–35. doi:10.1016/j.maturitas.2016.05.013. PMID 27451318.

Template:WH Template:WS